93
Prostaglandin E2 Drives Inflammation and Pain in Tendinopathy
Full Title
Divergent roles of prostacyclin and PGE2 in human tendinopathy.
Summary
This laboratory study investigated the role of prostaglandins, specifically prostaglandin E2 (PGE2) and prostacyclin, in driving inflammation and pain in human tendinopathy. The researchers examined tendon biopsies from patients with symptomatic tendinopathy or tendon rupture, as well as healthy comparator tendons. They found that diseased tendon tissue showed increased expression of enzymes responsible for producing prostaglandins, including COX-1 and COX-2, which are the exact enzymes that NSAIDs like ibuprofen work to block. When tendon cells from diseased tissue were stimulated with an inflammatory trigger, they released large amounts of PGE2, while cells from healthy tendons did not. The researchers determined that PGE2 sustains inflammation and pain in tendon disease, while prostacyclin appears to have a protective role. Importantly, when diseased tendon cells were treated with naproxen, a standard NSAID, both PGE2 and prostacyclin production were inhibited. This study provides direct molecular evidence that the inflammatory pathway targeted by NSAIDs is active and driving pain in tendinopathy. The COX enzymes that NSAIDs inhibit are upregulated in diseased tendons, and the PGE2 they produce is responsible for sustaining the inflammatory cycle. This supports the targeted use of NSAIDs to reduce PGE2-driven inflammation in tendon conditions, while also highlighting the importance of dose control to avoid suppressing the potentially protective prostacyclin pathway.